Evidence Snapshot

Carbonic anhydrase 9

CHEMBL3594 SINGLE PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:44Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 12:22 PM KST As of · Sep 14, 2026

ChEMBL ChEMBL 36 CHEMBL3594

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Carbonic anhydrase 9 as ChEMBL target CHEMBL3594, mapped to UniProt Q16790. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Carbonic anhydrase 9

SINGLE PROTEIN · Homo sapiens

As of 2026-09-14

ChEMBL target ID

CHEMBL3594

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-14

www.ebi.ac.uk

UniProt accession

Q16790

Carbonic anhydrase 9

UniProt accession via ChEMBL component mapping As of 2026-09-14

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-14

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Carbonic anhydrase 9 matters

As of 2026-09-14

Carbonic anhydrase 9 is reviewed as Carbonic anhydrase 9 (UniProt Q16790); Carbonic anhydrase 9 shows late clinical disease relevance led by renal cell carcinoma. 3 more disease programs remain visible in the same review block.; 3 linked drugs keep this evidence frame grounded.; the current evidence base includes 42 approved drugs, 6706 compounds, and 723 assays, with lead potency reaching pChEMBL 11.0.

Protein context

Carbonic anhydrase 9

Carbonic anhydrase 9 Sequence length is 459 aa.

Review this target as Carbonic anhydrase 9, mapped to UniProt Q16790. Sequence length is 459 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt Q16790 Protein

Disease context

renal cell carcinoma

Carbonic anhydrase 9 shows late clinical disease relevance led by renal cell carcinoma. 3 more disease programs remain visible in the same review block. 3 linked drugs keep the rationale reviewable. 3 additional disease programs remain visible in the same card. Linked drugs include CG250 111IN, CG250 177LU, GIRENTUXIMAB.

Start review with renal cell carcinoma because it currently carries late clinical support. Linked drugs include CG250 111IN, CG250 177LU, GIRENTUXIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Late clinical 3 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 42 approved drugs, 6706 compounds, and 723 assays for this target. The dominant activity type is KI. CHEMBL4456851 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL4456851 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine

42 approved pChEMBL 11.0

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Carbonic anhydrase 9 matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q16790, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why renal cell carcinoma is currently treated as late clinical support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

6706

Total Compounds

723

Total Assays

Approved Drugs

IC50: 388.0, KI: 7098.0, KD: 522.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL4456851	11.0	Kd	—
No preferred name CHEMBL4543024	11.0	Kd	—
No preferred name CHEMBL4551069	11.0	Kd	—
No preferred name CHEMBL4553519	11.0	Kd	—
No preferred name CHEMBL4558287	11.0	Kd	—

Approved Drugs

Structure	Compound	First Approval
	PAZOPANIB CHEMBL477772	2009
	LACOSAMIDE CHEMBL58323	2008
	NILOTINIB CHEMBL255863	2007
	IMATINIB CHEMBL941	2001
	VALDECOXIB CHEMBL865	2001
	ZONISAMIDE CHEMBL750	2000
	BRINZOLAMIDE CHEMBL220491	1998
	CELECOXIB CHEMBL118	1998
	TOPIRAMATE CHEMBL220492	1996
	DORZOLAMIDE CHEMBL218490	1994
	FAMOTIDINE CHEMBL902	1986
	SULFANILAMIDE CHEMBL21	1985
	INDAPAMIDE CHEMBL406	1983
	ETHOXZOLAMIDE CHEMBL18	1982
	MAFENIDE CHEMBL419	1969
	FUROSEMIDE CHEMBL35	1966
	TRICHLORMETHIAZIDE CHEMBL1054	1960
	CHLORTHALIDONE CHEMBL1055	1960
	METHAZOLAMIDE CHEMBL19	1959
	DICHLORPHENAMIDE CHEMBL17	1958
	ACETAZOLAMIDE CHEMBL20	1953
	PROBENECID CHEMBL897	1951

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:44Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 12:22 PM KST As of · Sep 14, 2026

ChEMBL ChEMBL 36 CHEMBL3594